Established in 2015 and based in France, with executive management in USA , SafeHeal is a clinical-stage medical device manufacturer and a leading innovator in the field of colorectal cancer surgery. The company specializes in the development of anastomosis protection devices designed to eliminate the need for diverting ostomies in patients undergoing colectomy. Its flagship product, Colovac™, is a groundbreaking temporary endoluminal fecal bypass system that serves as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.
Feasibility and pilot clinical trials indicate that Colovac, by eliminating the need for a temporary stoma in the majority of low anterior cancer resection patients, may improve and expedite recovery from colorectal surgery. This is an especially important benefit for surgeons, clinicians, and postoperative care professionals, and for the community of colorectal cancer patients worldwide.
SafeHeal recently completed an oversubscribed €35 million Series C equity financing to validate the use of Colovac, with proceeds supporting completion of its IDE Pivotal study and accelerating preparation for commercial launch. In addition, the company closed an extension Series C round for an additional €10 million.
Safeheal announced in August 2025 that they received European CE approval and expect to begin European commercialization in the 1st quarter of 2026. Safeheal is currently beginning US FDA clinical studies.
Solar Eclipse, an SPV formed by Marty and Steven Sands to lead the Series C were joined by JJDC, the venture arm of Johnson and Johnson, Sofinova, Assabys, and Gideon Strategic to help advance SafeHeal’s mission to transform post-surgical recovery and outcomes for colorectal patients.
